IpsenIPSEF 95 EBITDA Margin % is 30.65% as of Dec. 2025, which is 2% above its 10-year median of 30.02. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Ipsen ranks better than 88.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ipsen's EBITDA for the
six
months ended in Dec. 2025 was $715 Mil. Ipsen's Revenue for the
six
months ended in Dec. 2025 was $2,333 Mil. Therefore, Ipsen's EBITDA margin for the quarter that ended in Dec. 2025 was 30.65%.
Ipsen (OTCPK:IPSEF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ipsen EBITDA Margin % Related Terms
Ipsen EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ipsen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPSEF vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ipsen's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (IPSEF) has a EBITDA Margin % of 30.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ipsen and its competitors. This is near median its historical median of 30.02. Over the past decade, Ipsen's EBITDA Margin % has ranged from 5.69 to 38.54. According to the industry distribution chart, Ipsen ranks #109 out of 955 companies in the Drug Manufacturers industry, placing it in the top 11.4%.
Is Ipsen's EBITDA Margin % too high?
Ipsen's current EBITDA Margin % of 30.65% is near median its 10-year median of 30.02. Over the past 10 years, this metric has ranged from a low of 5.69 to a high of 38.54. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Ipsen's value of 30.65% is 147.4% above this industry median. Based on the distribution chart, Ipsen ranks #109 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #109 out of 955 companies for EBITDA Margin %. This places Ipsen in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Ipsen's value of 30.65% is 147.4% above this benchmark. Historically, Ipsen's own EBITDA Margin % has ranged from 5.69 to 38.54 over the past decade. While the company's 10-year median is 30.02 vs. the industry median of 12.39, Ipsen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current EBITDA Margin % of 30.65% is 147.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current EBITDA Margin % is 30.65%, which is near median its own 10-year median of 30.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current EBITDA Margin % of 30.65%. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current EBITDA Margin % is 30.65%, which is near median its 10-year median of 30.02 and 147.4% above the Drug Manufacturers industry median of 12.39. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ipsen (IPSEF), the current EBITDA Margin % is 30.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (IPSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.
Key valuation signals for IPSEF:
EBITDA Margin %: 30.65% (near median its 10-year median of 30.02)
GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
Industry Position: 147.4% above the Drug Manufacturers median (#109 of 955)
No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score
Get the complete analysis for IPSEF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSEF has been successfully added to your 
